An K-Y et al. Exercise and health-related fitness predictors of chemotherapy completion in breast cancer patients: Pooled analysis of two multicenter trials. Breast Cancer Res Treat 2021;188(2):399-407. Abstract
Barcenas CH et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: The CONTROL trial. Ann Oncol 2020;31(9):1223-30. Abstract
Choong GM et al. Evolving standards of care and new challenges in the management of HER2-positive breast cancer. CA Cancer J Clin 2020;70(5):355-74. Abstract
Curigliano G et al. Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). ASCO 2021;Abstract 1043.
Hamilton E et al. Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. San Antonio Breast Cancer Symposium 2020;Abstract PD3-08.
Holmes FA et al. Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial. San Antonio Breast Cancer Symposium 2020;Abstract PD3-03.
Jerusalem GHM et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINYBreast01 trial. ASCO 2021;Abstract 526.
Kirkham AA et al. Impact of exercise on chemotherapy tolerance and survival in early-stage breast cancer: A nonrandomized controlled trial. J Natl Compr Canc Netw 2020;18(12):1670-7. Abstract
Lin NU et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol 2020;38(23):2610-9. Abstract
Mamounas EP et al. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: Subgroup analyses from KATHERINE. Ann Oncol 2021;32(8):1005-14. Abstract
Modi S et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: Results from a phase Ib study. J Clin Oncol 2020;38(17):1887-96. Abstract
Modi S et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2020;Abstract PD3-06.
Mueller V et al. Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). Eur J Cancer 2021;153:223-33. Abstract
Naik H et al. Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer. ASCO 2021;Abstract e18791.
Okines AFC et al. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). ASCO 2020;Abstract 1043.
Rugo HS et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol 2021;7(4):573-84. Abstract
Tesch ME, Gelmon KA. Targeting HER2 in breast cancer: Latest developments on treatment sequencing and the introduction of biosimilars. Drugs 2020;80(17):1811-30. Abstract
Tolaney SM et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial. J Clin Oncol 2021;39(21):2375-85. Abstract
Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384(25):2394-405. Abstract
Wardley A et al. Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases. San Antonio Breast Cancer Symposium 2020;Abstract PD13-04.
Yuan Z et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The SYSUCC-002 randomized clinical trial. ASCO 2021;Abstract 1003.